×
About 2,083 results

ALLMedicine™ Hypophosphatemia Center

Research & Reviews  677 results

Osteocytes but not osteoblasts directly build mineralized bone structures.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315029
International Journal of Biological Sciences; Wang K, Ren Y et. al.

Jul 31st, 2021 - Bone-forming osteoblasts have been a cornerstone of bone biology for more than a century. Most research toward bone biology and bone diseases center on osteoblasts. Overlooked are the 90% of bone cells, called osteocytes. This study aims to test t...

Hypophosphatemia in acute liver failure of a broad range of etiologies is associated wi...
https://doi.org/10.1016/j.trsl.2021.07.003
Translational Research : the Journal of Laboratory and Cl... Zechner C, Adams-Huet B et. al.

Jul 24th, 2021 - Hypophosphatemia is a common and dangerous complication of acute liver failure (ALF) of various etiologies. While various mechanisms for ALF-associated hypophosphatemia have been proposed including high phosphate uptake into regenerating hepatocyt...

A Case of Hypophosphatemia due to Oncogenic Osteomalacia in a Patient with Natural Kill...
https://doi.org/10.1159/000516390
Kidney & Blood Pressure Research; Zheng G, Kanduri SR et. al.

Jul 23rd, 2021 - Oncogenic osteomalacia (Onc-Ost) is a paraneoplastic phenomenon characterized by hypophosphatemia due to elevated fibroblast growth factor-23 (FGF-23). Onc-Ost has been previously reported in patients with germ line mesenchymal tumors and solid or...

Magnetic Resonance Imaging is a valuable tool to evaluate the therapeutic efficacy of b...
https://doi.org/10.1530/EJE-21-0429
European Journal of Endocrinology; Zhukouskaya VV, Mannes I et. al.

Jul 23rd, 2021 - to examine the MRI diagnostic performance in assessment of therapeutic response to burosumab in children with X-linked hypophosphatemia (XLH). prospective longitudinal open cohort. 17 children with XLH, average age of 10.2±2.7 years, had a knee MR...

Hypophosphatemia in critically ill pediatric patients receiving enteral and oral nutrit...
https://doi.org/10.1002/jpen.2235
JPEN. Journal of ParEnteral and Enteral Nutrition; de Mattos Springer AM, Hortencio TDR et. al.

Jul 23rd, 2021 - Hypophosphatemia (HP) is related to several comorbidities in pediatric intensive care units (PICUs). This study aimed to evaluate the incidence of HP in severely ill pediatric patients under oral and/or enteral nutrition. The secondary objectives ...

see more →

Drugs  91 results see all →

Clinicaltrials.gov  24 results

X-linked Hypophosphatemia Disease Monitoring Program
https://clinicaltrials.gov/ct2/show/NCT03651505

Apr 3rd, 2020 - The XLH-DMP is a global, prospective, multicenter, longitudinal, long-term outcomes program for subjects on or off any treatment designed to characterize XLH disease presentation and progression, assess long-term safety and effectiveness of burosu...

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
https://clinicaltrials.gov/ct2/show/NCT03237065

Feb 25th, 2020 - This trial was designed to evaluate the effect of IV iron isomaltoside/ferric derisomaltose compared with IV ferric carboxymaltose on s-phosphate in subjects with IDA caused by different etiologies. The subjects received either a single intravenou...

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
https://clinicaltrials.gov/ct2/show/NCT03238911

Feb 25th, 2020 - This trial was designed to evaluate the effect of IV iron isomaltoside/ferric derisomaltose compared with IV ferric carboxymaltose on s-phosphate in subjects with IDA caused by different etiologies. The subjects received either a single intravenou...

Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
https://clinicaltrials.gov/ct2/show/NCT02526160

Dec 27th, 2019 - The primary efficacy objective of this study is to establish the effect of burosumab treatment compared with placebo on increasing serum phosphorus levels in adults with XLH.

Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
https://clinicaltrials.gov/ct2/show/NCT02537431

Dec 23rd, 2019 - The primary objective of this study is to establish the effect of KRN23 treatment on improvement in XLH-associated osteomalacia as determined by osteoid volume (osteoid volume/bone volume, OV/BV).

see more →

News  41 results

Entinostat Doesn't Overcome Endocrine Resistance in Breast Cancer
https://www.medscape.com/viewarticle/944005

Jan 13th, 2021 - The histone deacetylase (HDAC) inhibitor entinostat failed to overcome resistance to endocrine therapy in hormone receptor–positive, HER2-negative, advanced breast cancer in a phase 3 trial. The study showed no difference in response, progression-...

Study Supports Citrate Over Heparin Anticoagulation for Continuous Dialysis
https://www.medscape.com/viewarticle/939781

Oct 27th, 2020 - NEW YORK (Reuters Health) - A large randomized controlled trial supports the use of regional citrate over heparin anticoagulation to help prevent blood clot formation at the filter in patients receiving continuous dialysis therapies. Dialysis filt...

Burosumab Is a 'Game Changer,' Effective in All Subgroups of XLH
https://www.medscape.com/viewarticle/937820

Sep 22nd, 2020 - A recently approved agent, burosumab (Crysvita), was better than placebo across a range of efficacy outcomes for 14 predefined subgroups of adults with X-linked hypophosphatemia (XLH), new research shows. The authors analyzed data from the initial...

Burosumab Is a 'Game Changer,' Effective in All Subgroups of XLH
https://www.staging.medscape.com/viewarticle/937820

Sep 22nd, 2020 - A recently approved agent, burosumab (Crysvita), was better than placebo across a range of efficacy outcomes for 14 predefined subgroups of adults with X-linked hypophosphatemia (XLH), new research shows. The authors analyzed data from the initial...

Burosumab Shows Sustained Efficacy in Rare Inherited Rickets
https://www.medscape.com/viewarticle/919315

Oct 2nd, 2019 - ORLANDO, Florida — Burosumab (Crysvita, Ultragenyx), an anti-FGF23 monoclonal antibody, shows long-term safety and efficacy out to almost 2 years in the treatment of X-linked hypophosphatemia (XLH), a rare, inherited form of rickets, according to ...

see more →